Revenue
No reported data
Parabilis Medicines, Inc. (PBLS)
Price—Loading quote
Net income
2024
2025
Free cash flow
2024
2025
Total cash / debt
CashTotal debt
2025
2026
Financial statements
| 2025 | 2024 | |
|---|---|---|
| Research & development | $125.6M | $100.8M |
| Operating income | −$152.1M | −$126.1M |
| EBITDAderived | −$149.6M | −$124.0M |
| Net income | −$145.9M | −$117.9M |
| Diluted EPSper diluted share | -$92.40 | -$83.48 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 15, 2026Form 4 | SEBULSKY ALANDirector | BuyCommon Stock · indirect | 4.1K | $27.10 | $110.2K | 30.0K |
| Jun 15, 2026Form 4 | SEBULSKY ALANDirector | BuyCommon Stock · indirect | 5.0K | $26.00 | $130.0K | 25.9K |
| Jun 12, 2026Form 4 | SEBULSKY ALANDirector | BuyCommon Stock · indirect | 8.4K | $27.67 | $233.4K | 20.9K |
| Jun 11, 2026Form 4 | Soleus Capital Group, LLC +8TenPercentOwner | BuyCommon Stock, par value $0.0001 per share · indirect | 125.0K | $20.00 | $2.50M | 652.0K |
| Jun 11, 2026Form 4 | Soleus Capital Group, LLC +8TenPercentOwner | BuyCommon Stock, par value $0.0001 per share · indirect | 375.0K | $20.00 | $7.50M | 1.03M |